<- Go Home
Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Market Cap
$72.7M
Volume
29.1K
Cash and Equivalents
N/A
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$49.00
52 Week Low
$0.85
Dividend
N/A
Price / Book Value
4.04
Price / Earnings
-3.53
Price / Tangible Book Value
4.04
Enterprise Value
$72.7M
Enterprise Value / EBITDA
N/A
Operating Income
-$18.9M
Return on Equity
85.28%
Return on Assets
-24.23
Cash and Short Term Investments
N/A
Debt
N/A
Equity
$17.0M
Revenue
N/A
Unlevered FCF
$7.1M
Sector
Biotechnology
Category
N/A